Treatment-Resistant Depression Research Study
University of Alabama at Birmingham researchers are seeking volunteers for a study on liafensine to treat depression. Join today!
Huntsville, AL
Compensation Provided
History of Treatment-Resistant Depression
18 - 70 Years Old
Fast Facts
Study Background
Do you have a history of treatment-resistant depression?
UAB researchers are testing the effectiveness of a medication called liafensine for people whose depression has not responded to other treatments. If you have tried at least two treatment courses with antidepressant therapy and they did not work for you, then you may qualify to join this study.
Your participation may lead to better treatments for depression in the future. Help advance research and enroll today!
UAB researchers are testing the effectiveness of a medication called liafensine for people whose depression has not responded to other treatments. If you have tried at least two treatment courses with antidepressant therapy and they did not work for you, then you may qualify to join this study.
Your participation may lead to better treatments for depression in the future. Help advance research and enroll today!
Study Background Do you have a history of treatment-resistant depression? UAB researchers are testing the effectiveness of a medication called liafensine for people whose depression has not responded to other treatments. If you have tried at least two treatment courses with antidepressant therapy and they did not work for you, then you may qualify to join this study. Your participation may lead to better treatments for depression in the future. Help advance research and enroll today! |
Additional Information
The study aims to evaluate the effectiveness of liafensine on treatment-resistant depression.
You may qualify to participate in this study if you meet the following criteria.
Inclusion Criteria:
Inclusion Criteria:
- Ages 18 to 70
- Diagnosis of major depressive disorder (MDD) without psychotic features
- Have tried at least 2 different antidepressant treatments in the past 5 years
- Willing to discontinue antidepressant treatments at least 2 weeks before the study begins
- Able to pass urine drug screen
- Pregnant or breastfeeding
- Uncontrolled liver disease
- Uncontrolled HIV
- History of seizures or significant head trauma
- History of cancer within the past 2 years
- Use of prescription or nonprescription medications for ADHD, narcolepsy, or cognitive enhancement in the past 30 days
- Current diagnosis of a psychotic disorder, bipolar disorder, PTSD, OCD, or a personality disorder
- Substance use disorder within the past 6 months
- Active suicidality within the past year
- Used an investigational drug product, device, or biologic within the past 6 months
If eligible, your participation in the study will involve up to 9 visits over about 11 weeks.
Part 1, the screening portion, can last up to 3 weeks over 2 visits. The first visit involves informed consent, medical history, health screen, and a blood test for a biomarker. The second visit involves psychological assessments, questionnaires, physical and neurological exam, and health exams.
Part 2, the study treatment portion, lasts up to 4 weeks over 5 visits. These involve questionnaires, physical and neurological exam, health screen, and dispensing either the study drug or placebo.
Part 3, the follow-up portion, is two visits: two weeks after the last dose and 28 days after the last dose. These involve questionnaires and a health exam.
Part 1, the screening portion, can last up to 3 weeks over 2 visits. The first visit involves informed consent, medical history, health screen, and a blood test for a biomarker. The second visit involves psychological assessments, questionnaires, physical and neurological exam, and health exams.
Part 2, the study treatment portion, lasts up to 4 weeks over 5 visits. These involve questionnaires, physical and neurological exam, health screen, and dispensing either the study drug or placebo.
Part 3, the follow-up portion, is two visits: two weeks after the last dose and 28 days after the last dose. These involve questionnaires and a health exam.
Eligible participants will be compensated up to $100 per visit.
There is no cost for you to participate in our research program.